Business Wire - March 13, 2000
SDS will begin the process of obtaining FDA approval for its whole blood HIV1/2 rapid test using its patented Capillary Barrel System. SDS believes initial conversations with US government agencies have been extremely positive, and furthermore the Company is encouraged by their test results.
"As we move forward in a new and positive direction, SDS is committed toward developing only products and markets that have the greatest chances of commercial viability," stated Leo Ehrlich, President & CEO of SDS. "Management will work vigorously to make its patented Capillary Barrel System the standard in medical rapid testing. SDS's new management has defined the direction of its business plan following the closure of the Vancouver facility. The SDS business model includes seeking FDA approval for US sales of its HIV1/2 product; developing additional tests for its Capillary Barrel System; completion of a saliva base substance abuse test; and the licensing of its patents to other companies."
Mr. Ehrlich closed his remarks by saying, "I would like to acknowledge the hard, smart work and dedication of certain individuals. Our teamwork and efforts have greatly increased the chances for the long-term success of the Company. We will continue on our course to make SDS a successful viable company dedicated to developing the finest products to enhance life."
For more information on SALV, please visit the Company's Web site at http://www.salv.com
FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
CONTACT: Saliva Diagnostic Systems, Inc., New York Leo Ehrlich Tel: (212) 937-3801 leo@salv.com
Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .